Wed, Oct. 21, 12:49 PM
Wed, Oct. 21, 12:18 PM
- Northwest Biotherapeutics (NWBO +2.4%) inks an agreement with Woodford Investment Management for $30M in new capital via Woodford's purchase of 5,454,545 shares of NWBO common stock at $5.50 per share. The buy raises Woodford's stake to 28.1% (25,915,937 shares) of the company.
- NWBO also issues 700K shares to Cognate BioServices for certain payment obligations and to complete the issuance of shares approved and reported in November 2014.
- Net proceeds will fund the continued advancement of DCVax-L and the hiring of new personnel.
Mon, Oct. 19, 12:43 PM
Mon, Oct. 19, 11:22 AM
- In a statement released today, Northwest Biotherapeutics (NWBO +11.5%) says it is unaware of any fundamental reason that would have precipitated Friday's 29% sell-off on triple normal volume. It says it presented positive clinical data at scientific meetings as late as mid-September.
- On Thursday afternoon, the Financial Times published an article by Judith Evans titled, "Biotech sell-off hurts Woodford trust and specialist funds." Northwest was cited in the piece as one of the contributors to a one-month NAV loss of over 6% in the Woodford Patient Capital Trust, launched in April. The article's role in Friday's action is, of course, unknowable.
Mon, Aug. 24, 12:46 PM
Fri, Aug. 21, 9:13 AM
- Northwest Biotherapeutics (NASDAQ:NWBO) is down 11% premarket on light volume in apparent response to the disclosure of a temporary halt to its Phase 3 DCVax-L clinical trial in Germany. The reason for the action is not provided.
- Update: In a press release, the company clarifies that the screening of new patients has been temporarily suspended while the company submits "certain information" from the trial for regulatory review. The nature of the information is not specified, but Northwest expects to submit it in the next few weeks. Patients already enrolled, over 300, are continuing to be treated per the study protocol. Total anticipated enrollment is 348 subjects.
Fri, Mar. 27, 12:57 PM
- At the 2nd Annual Immunotherapy of Cancer Conference in Munich, Germany, Northwest Biotherapeutics' (NWBO +6.6%) Chief Technology Officer Dr. Marnix Bosch presented data from an Information Arm of 51 patients with glioblastoma multiforme (GBM) treated with DCVax-L. They were treated outside of the company's Phase 3 study because they were not eligible due to evidence of early tumor re-growth following six weeks of standard-of-care treatment with radiotherapy and chemotherapy. The data showed longer-than-expected survival.
- Overall survival data were generated for all 51 patients, but only 46 had MRI images available. Patients in this group were classified as Rapid Progressors (n=20) (patients with a new lesion of at least 1 cm in size or tumor growth at least 25% both at baseline visit and Month 2), Indeterminate (n=25) (evidence of progression at baseline visit followed by stable disease or modest progression/regression) or Pseudo-Progressor (n=1) (Month 2 MRI showed resolution of most of tumor growth seen at baseline visit).
- Median overall survival (OS) of the 51 patients was 18.3 months, with ~30% living beyond two years. Median OS for Rapid Progressors, the ones with the poorest prognoses, was 15.3 months. Median OS for Indeterminates was 21.5 months. The Pseudo-Progressor is still alive (30.1 months to date). The results reflect as much as a 50% improvement over expected OS.
- The Phase 3 trial assessing DCVax-L in GBM is ongoing.
Thu, Feb. 19, 4:31 PM
- Health Canada approves the start of Northwest Biotherapeutics' (NASDAQ:NWBO) ongoing Phase 3 clinical trial of DCVax-L in glioblastoma multiforme (GBM) brain cancer. The study will be performed at two sites, the Montreal Neurological Institute and Hospital and Quebec's Centre Hospitalier Uninversitaire de Sherbrooke, Hopital Fleurimont. The approval processes have been completed at both sites and patient screening for enrollment is underway.
- The 348-patient study is being conducted at 51 sites in the U.S. and additional sites in Europe. The lead site is Kings College Hospital in London. The primary efficacy endpoint is progression-free survival.
- DCVax is comprised of activated dendritic cells which are designed to boost the immune system to fight cancer.
Sep. 30, 2014, 11:00 AM
- TheStreet's Editor-In-Chief Janet Guyon writes an extensive rebuttal to an article published on September 27 by the Washington Post's Steven Pearlstein where he accuses Adam Feuerstein of being in bed with short sellers regarding Northwest Biotherapeutics (NWBO -1.9%). In short, he accuses AF of securities fraud.
- TheStreet, unsurprisingly, takes exception to the piece saying Mr. Feuerstein does not own shares in NWBO, is not in cahoots with any hedge funds and supports his articles with facts. Ms. Guyon requests a retraction.
- Many observers will undoubtedly find the situation humorous considering AF's confrontational style. Mr. Pearlstein, however, questions his integrity which is out of bounds without the facts to back it up.
Sep. 16, 2014, 9:20 AM
Sep. 16, 2014, 8:53 AM
- Northwest Biotherapeutics (NASDAQ:NWBO) is up 10% premarket on good volume in response to its announcement that U.K. authorities have designated DCVax-L as a Promising Innovative Medicine (PIM) under its new Early Access to Medicines Scheme. The program, launched in April of this year, provides for accelerated approval for promising new therapies that address a serious disease or condition with high unmet medical need. It is akin to the U.S. FDA's Breakthrough Therapy Designation (BTD).
- PIM approval is a two-step process. Step one is an evaluation by the Medicines and Healthcare Products Regulatory Agency (MHRA) to determine if the product meets three criteria: 1. it addresses the aforementioned serious disease or condition with high unmet medical need; 2. the product is likely to offer a major advantage of available treatments; 3. the potential benefits outweigh the potential adverse effects. Step two is an evaluation of the clinical data to assess the product's benefits and risks. If MHRA's opinion is positive, the product may then be prescribed by physicians before it is formally licensed and while it is still in clinical development.
Aug. 25, 2014, 4:41 PM
- Northwest Biotherapeutics (NWBO -2.1%) closes a $17.5M convertible note paying 5% interest for a term of three years. The notes are convertible into common stock at $7.50 per share. Investors also have three-month option to buy an additional 30% of the notes.
- Proceeds will be used to fund increased manufacturing capacity and ongoing clinical trials.
- NWBO shares closed today at $5.98.
Jul. 8, 2014, 6:22 PM
- Northwest Bio (NWBO) CEO Linda Powers denies charges contained in yesterday's Seeking Alpha article by Richard Pearson that the driving force behind gains in the stock price is a string of promotional pieces, asserting that the author didn't mention "the real reason, that the company has made tremendous operational progress."
- Pearson contended that "many of the authors who have written on Northwest are using fake identities and fake credentials. They pretend to be biologists, other scientists, or fund managers. In fact, they are just paid writers."
- Powers says NWBO has a business relationship with an outside investor relations firm that promotes the company on social media sites, but that writers are not commissioned to write puff pieces, as Pearson alleges.
- NWBO has dropped nearly 7% since Pearson's story was posted Monday morning.
Jun. 20, 2014, 9:18 AM
- Northwest Biotherapeutics (NWBO) asserts that Mr. Feuerstein's June 19 article is misleading and inaccurate. For starters, it says that has not received a "rebuke" from any clinical trial site nor is there a basis to receive one. It claims that it has consistently stated that it would release interim data on an ongoing basis regarding the DCVax-Direct Phase 1/2 clinical trial. It confirms that the disclosed data originated from medical files sent to the company from the trial sites and a CRO, but it claims that reporting interim results is not unusual for an unblinded open-label study like DCVax.
- CEO Linda Powers says, "...Feuerstein seeks ever more sensationalized ways to try to smear the Company. This is not even the semblance of professional analysis. We condemn this attack campaign and appreciate the strong support we are receiving from shareholders, patients and other commentators. We intend to continue our progress undeterred."
Jun. 19, 2014, 12:45 PM
Jun. 19, 2014, 10:37 AM
- MD Anderson VP of Clinical Research Aman Buzdar, M.D., takes issue with Northwest Biotherapeutics' (NWBO -10.4%) trigger-happy behavior regarding disclosing preliminary and unconfirmed results from the ongoing DCVax clinical trial. The company has issued five press releases and conducted one conference call disclosing the results from individual cancer patients who have had single inoperable tumors injected with DCVax-Direct. This is problematic due to two issues: 1) the investigators have not reviewed or analyzed the data because patients are still being enrolled and treated and 2) NWBO's published "results" come from patient case report forms which the trial sites are obligated to send to the trial sponsor.
- Dr. Buzdar says, "I have read the information that the company has put in the public domain. It is extremely unusual and inappropriate." He terms the company's disclosures inappropriate because injecting a tumor with any substance can cause regression due to necrosis-causing inflammation. He says, "..it is a tremendous leap to say that this is a real response."
Northwest Biotherapeutics Inc is a development stage biotechnology company engaged in the development of immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies.
Other News & PR